EP1087784A1 - Synthetic somatostatin immunogen for growth promotion in farm animals - Google Patents
Synthetic somatostatin immunogen for growth promotion in farm animalsInfo
- Publication number
- EP1087784A1 EP1087784A1 EP99931846A EP99931846A EP1087784A1 EP 1087784 A1 EP1087784 A1 EP 1087784A1 EP 99931846 A EP99931846 A EP 99931846A EP 99931846 A EP99931846 A EP 99931846A EP 1087784 A1 EP1087784 A1 EP 1087784A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- peptide
- somatostatin
- peptide conjugate
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the immunogenic peptides of the subject composition contain helper T cell epitopes (Th) which comprise multiple class II MHC binding motifs and have somatostatin at either the C- or N- terminus.
- the peptides optionally, contain an invasin domain which acts as a general immune stimulator.
- the helper T cell epitopes and the invasin domain enable the immune response against the somatostatin self-peptide .
- the principal somatotrophic hormones are: somatotropin (growth hormone, GH) , somatomedin-C (msulin-like growth factor 1, IGF-1), somatocrinm (GH releasing factor, GRF) and somatostatin (GH release inhibiting factor) .
- somatotropin growth hormone
- somatomedin-C msulin-like growth factor 1, IGF-1
- somatocrinm GH releasing factor, GRF
- somatostatin GH release inhibiting factor
- GH plays two distinct roles. It has a positive effect in stimulating an increase in muscle protein synthesis (most, if not all, of which is mediated by IGF-1) and a potent catabolic effect by its ability to breakdown fats.
- the overall effects are an increase in the lean content of the carcass and a decrease in carcass fat, often an increase in growth, and universally an improvement in food conversion efficiency (Buttery and Dawson, Proc Nutr Soc, 1990; 49:459; and, Spencer, Reprod Nutr Develop, 1987; 27 (2B) :581) .
- Somatostatin is a cyclic peptide of fourteen ammo acids and its structure is conserved across species. It is synthesized as a ninety-two ammo aci ⁇ prosomatostatm molecule from which six peptides including somatostatin itself and a twenty-eight ammo acid form of somatostatm are known to be derived (Reichlm, J Lab Clin Me ⁇ , -987; 109:320). Somatostatin inhibits the release of many gastro-mtestmal hormones as well as inhibits release of GH, insulin, thyroid hormones, thereby affecting both tne ability of the animal to absorb nutrients and its subsequent ability to direct these nutrients into tissue growth.
- somatostatin antagonist has been found to stimulate growth n rats (Spencer et al . , Life Sc , 1985, 37:27), but this kind of treatment also suffers from the drawbacks of GH, IGF-1 and GRF n that it requires daily in j ections.
- a practical alternative is the use of the immune response to induce lmmunoneutralization of somatostatin.
- the use of the immune system to promote growth may be more acceptable to consumers and regulatory agencies than direct administration of hormones or synthetic steroids .
- the lmmunoneutralization of somatostatm by vaccine was first explored in sheep by Spencer et al . (Livest prod Sci, 1983, 10:469) . In a preliminary study using twin St.
- somatostatin protein carrier conjugates
- Most if not all of the somatostatin protein carrier conjugates were prepared by glutaraldehyde coupling, employing cross linkage between the lysine residues present on somatostatin and the carrier protein.
- the two lysines on somatostatin available for coupling reside within a 12-mer functional loop thus may result in significant loss of the native somatostatin structure and reduction in crossreactivity to somatostatin when such conjugates are used as vaccines.
- an immune enhancer that is suitable for live stock use, inexpensive and capable of stimulating an early and strong immune response to somatostatin has been sough . This immune enhancer should avoid carrier-induced suppression.
- T helper cell epitopes An important factor affecting immunogenicity of a synthetic peptide for an somatostatin immunogen is its presentation to the immune system by T helper cell epitopes. Formerly, those were provided by a carrier protein with the concomitant disadvantages discussed above. These may also be supplied as hybrid polypeptides by recombinant DNA expression systems (Riggs, US 4,812,554; US 4,563,424; and Xu et al . ,
- a wholly synthetic peptide immunogen for somatostatin would enjoy the following advantages over carrier conjugates and recombinant polypeptides : the product is chemically defined for easy quality control, it is stable, no elaborate downstream processing is needed, no elaborate production plant is required, and the engendered immune response is site- specific so that undesirable responses such as epitopic suppression are avoided.
- Immunogenicity of synthetic somatostatin immunogens can be optimized by (1) combining somatostat with selected promiscuous Th sites to which the majority of a population are responsive; (2) combining somatostatin with an enlarged repertoire of Th through combinatorial chemistry and thereby accommodate to the variable immune responsiveness of a population, and (3) the stabilization of a desirable conformational feature of somatostatm by cyclic constraint.
- Promiscuous Th evoke efficient T cell help and can be combined with B cell epitopes that by themselves are poorly lmmunogenic to provide potent immunogens.
- Well-designed promiscuous Th/B cell epitope chimeric peptides are capable of eliciting Th responses and resultant antibody responses m most members of a genetically diverse population expressing diverse MHC naplotypes .
- Promiscuous Th can be provided by specific sequences derived from potent immunogens including measles virus F protein and hepatitis B virus surface antigen. Many known promiscuous Th have been shown to be effective n potentiating a poorly lmmunogenic peptide corresponding to the decapeptide hormone LHRH (US 5,759,551) .
- Th epitopes range in size from approximately 15-30 ammo acid residues in length, often share common structural features, and may contain specific landmark sequences.
- a common feature is amphipathic helices, which are alpha-helical structures with hydrophobic ammo acid residues dominating one face of the helix and with charged and polar residues dominating the surrounding faces (Cease et al . , Proc Natl Acad Sci USA, 1987; 84: 4249-4253).
- Th epitopes frequently contain additional primary ammo acid patterns such as a Gly or charged residue followed by two to three hydrophobic residues, followed in turn by a charged or polar residue. This pattern defines what are called Rothbard sequences.
- Th epitopes often obey the 1, 4, 5, 8 rule, where a positively charged residue is followed by hydrophobic residues at the fourth, fifth and eighth positions after the charged residue. Since all of these structures are composed of common hydrophobic, charged and polar amino acids, each structure can exist simultaneously within a single Th epitope (Partidos et al . , J Gen Virol, 1991; 72:1293). Most, if not all, of the promiscuous T cell epitopes fit at least one of the periodicities described above. These features may be incorporated into the designs of idealized artificial Th sites, including combinatorial Th epitopes.
- Peptide immunogens are generally more flexible than proteins and tend not to retain any preferred structure. Therefore it is useful to stabilize a peptide immunogen by the introduction of cyclic constraints.
- a correctly cyclized peptide immunogen can mimic and preserve the conformation of the targeted epitope and thereby evoke antibodies with cross- reactivities on that site on the authentic molecule (Moore, Chapter 2 in Synthetic Peptides A User' s guide, ed Grant, WH Freeman and Company: New York, 1992, pp 63-67) .
- Peptide immunogens that have been designed with the peptide technologies and peptide design elements discussed above, i.e., design of promiscuous potent Th epitopes, Th SSAL combinatorial peptides, and cyclic constraint, are the basis for effective synthetic somatostatin immunogens. Such peptides are preferred for their presentation of the somatostat by optimized positioning and cyclization, and for broadly reactive Th responsiveness.
- peptides containing particular structural arrangements of a Th epitope alone or linked to a general immune enhancer e.g., an invasin domain (US 5,759,551) and somatostatin its intact form where the functional site withm the 12 mer loop structure is not disturbed (as target antigen)
- a general immune enhancer e.g., an invasin domain (US 5,759,551)
- somatostatin its intact form where the functional site withm the 12 mer loop structure is not disturbed (as target antigen)
- the present mvention relates to an lmmunogenic peptide composition
- synthetic peptides which are capable of inducing antibodies against somatostat that lead to the suppression of somatostatin levels, promote growth and improve food conversion efficiency m farm animals.
- peptides of this mvention have a Th epitope linked to a carboxyl- or ammo- terminal somatostatin (SEQ IP NO:l) or a peptide analog of somatostatin.
- the peptides have an invasin domain (SEQ ID NO : 2 ) as a general immune stimulator.
- Another aspect of this invention provides an antigenic composition
- an antigenic composition comprising an immunologically effective amount of a peptide composition m accordance with this invention and one or more pharmaceutically acceptable vaccine formulations and instructions for dosage such that lmmunotherapeutic antibodies directed against the targeted somatostatin site are generated.
- Such peptide compositions are useful for growth promotion farm animals.
- a further aspect of the invention relates to a method for increasing circulating somatotropic hormone levels in a mammal by administering one or more of the subject peptides to the mammal for a time and under conditions sufficient to induce functional antibodies directed against said somatostatm.
- Yet another aspect of the invention relates to an lmmunogenic synthetic peptide of about 30 to about 90 ammo acids which contains a helper T cell (Th) epitope, somatostatin (SEQ IP NO:l) or a peptide analog of somatostatin, spacers to separate the lmmunogenic domains and optionally general immunostimulatory sites, for example, an invasin domain (SEQ ID NO:2).
- Thi helper T cell
- SEQ IP NO:l somatostatin
- spacers to separate the lmmunogenic domains and optionally general immunostimulatory sites, for example, an invasin domain (SEQ ID NO:2).
- This invention is directed to a novel peptide composition for the generation of high titer polyclonal antibodies with specificity for somatostatin.
- the high site- specificity of the peptide composition minimizes the generation of antibodies that are directed to irrelevant sites on carrier proteins. Therefore, the invention is further directed to an effective method for the growth promotion farm animals .
- Somatostatm is a short cyclized peptide hormone which, by itself is non-immunogenic, more so for being a self-antigen.
- This short peptide can be immunopotentiated by chemical coupling to a carrier protein, for example, keyhole limpet hemocyanm (KLH) or by fusion to a carrier polypeptide through recombinant DNA expression, for example, hepatitis B surface antigen.
- KLH keyhole limpet hemocyanm
- Major deficiencies of such "somatostatm-car ⁇ er" vaccines is that the largest portion of antibodies generated by the combinations are the non-functional antibodies directed against the carrier protein or polypeptide and the potential for epitopic suppression.
- the immunogens of the present mvention are wholly synthetic peptides which minimize the generation of irrelevant antibodies to elicit an immune response more focused to somatostatin .
- somatostatin is a non- lmmunogenic T cell-dependent antigen, it is completely dependent on extrinsic Th epitopes for lmmunogenicity .
- These are provided for the peptides of the invention as covalently linked promiscuous Th epitopes.
- the immunogens of the invention are all of site-specific immunoreactivity to provide for effective growth promotion m livestock.
- the term "immunogen” referred to herein relates to a peptide composition which is capable of inducing antibodies against somatostatin, leading to inhibition or suppression of somatostatm levels in a mammal.
- the peptide composition of tne present invention includes peptides which contain promiscuous helper T cell epitopes (Th epitopes) .
- the peptides are covalently attached to the somatostatm peptide, with a spacer (e.g. Gly-Gly) , so as to be adjacent to either the N- or C-termmus of the target somatostatm peptide, in order to evoke efficient antibody responses.
- the immunogen may also comprise a generalized immunostimulatory element, for example, a domain of an invasin protein from the bacteria Yersinia spp (Brett et al . , Eur J Immunol, 1993, 23: 1608-1614) (SEQ ID NO:2).
- the invasin domain is attached through a spacer to a Th peptide.
- the peptides of this invention can be represented by the formulas:
- H 2 N is the N-terminal -NH 2 of the peptide conjugate, each A is independently an ammo acid or a general immunostimulatory sequence; each B is chosen from the group consisting of ammo acids, -NHCH(X)CH 2 SCH 2 CO-, -NHCH (X) CH 2 SCH 2 CO ( ⁇ -N) Lys-, -NHCH(X)CH 2 S-succ ⁇ n ⁇ m ⁇ dyl ( ⁇ -N)Lys-, and -NHCH (X) CH 2 S- (succmimidyl) -; each Th is independently a sequence of ammo acids that comprises a helper T cell epitope, or an immune enhancing analog or segment thereof; somatostatm peptide is somatostatin or a crossreactive and immunologically functional analog thereof;
- X is an ammo acid ⁇ -COOH or ⁇ -CONH 2 ; n is from 1 to about 10; m is from 1 to about 4; and o is from 0 to about 10.
- the peptide immunogen of the present invention comprises from about 20 to about 100 ammo acid residues, preferably from about 25 to about 80 ammo acid residues and more preferably from about 25 to about 65 ammo acid residues.
- A is an ammo acid or a general immunostimulatory element, e.g., Inv, it can be covalently linked to either the N-terminal of the peptide immunogen as shown by the formulas, or to the C-termmal (not shown) .
- A is an ammo acid
- it can be any non-naturally occurring or any naturally occurring ammo acid.
- Non-naturally occurring ammo acids include, but are not limited to, ⁇ -alanine, ornithme, norleucme, norvalme, hydroxyprolme, thyroxme, ⁇ -ammo butyric acid, homoserme, citrullme and the like.
- Naturally-occurring amino acids include alanme, argmme, asparagme, aspartic acid, cysteine, glutamic acid, glutamme, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
- m is greater than one, and two or more of the A groups are amino acids, then each amino acid may be independently the same or different.
- A When A is an invasin domain, it is an immune stimulatory epitope from the invasin protein of a Yersinia species. This immune stimulatory property results from the capability of this invasin domain to interact with the ⁇ l integrin molecules present on T cells, particularly activated immune or memory T cells.
- the specific sequence for an invasin domain found to interact with the ⁇ l integrins has been described by Brett et al ⁇ Eur J Immunol , 1993) .
- a preferred embodiment of the invasin domain (Inv) for linkage to a promiscuous Th epitope has been previously described in US 5,759,551 and is incorporated herein by reference.
- the said Inv domain has the sequence:
- SEQ ID NO:2 is an immune stimulatory homologue thereof from the corresponding region in another Yersinia species invasin protein.
- Such homologues thus may contain substitutions, deletions or insertions of amino acid residues to accommodate strain to strain variation, provided that the homologues retain immune stimulatory properties .
- n is 1 and A is -NH 2 . In another embodiment, n is 4 and A is -NH 2 , an invasin domain (Inv), glycine and glycine, in that order.
- Inv invasin domain
- B is a spacer and is an amino acid which can be naturally occurring or the non-naturally occurring amino acids as described above. Each B is independently the same or different.
- the amino acids of B can also provide a spacer, e.g., Gly-Gly, between the promiscuous Th epitope and the somatostatin peptide (e.g., SEQ ID NO:l) and crossreactive and functional immunological analogs thereof.
- the Gly-Gly spacer can disrupt any artifactual secondary structures created by the joining of the Th epitope with the somatostatin peptide and crossreactive and functional immunological analogs thereof and thereby eliminate interference between the Th and/or B cell responses .
- the amino acids of B can also form a spacer which acts as a flexible hinge that enhances separation of the Th and IgE domains . Examples of sequences encoding flexible hinges are found in the immunoglobulin heavy chain hinge region. Flexible hinge sequences are often proline rich.
- One particularly useful flexible hinge is provided by the sequence Pro-Pro-Xaa-Pro-Xaa-Pro (SEQ ID NO:3), where Xaa is any amino acid, and preferably aspartic acid.
- SEQ ID NO:3 Pro-Pro-Xaa-Pro-Xaa-Pro
- Xaa is any amino acid, and preferably aspartic acid.
- the conformational separation provided by the amino acids of B permits more efficient interactions between the presented peptide immunogen and the appropriate Th cells and B cells and thus enhances the immune responses to the Th epitope and the antibody-eliciting epitope and their crossreactive and functional immunological analogs thereof.
- Th is a sequence of amino acids (natural or non- natural amino acids) that comprises a Th epitope.
- a Th epitope can consist of a continuous or discontinuous epitope. Hence not every amino acid of Th is necessarily part of the epitope. Accordingly, Th epitopes, including analogs and segments of Th epitopes, are capable of enhancing or stimulating an immune response to the somatostatin peptide and immunological analogs thereof.
- Th epitopes that are immunodominant and promiscuous are highly and broadly reactive in animal and human populations with widely divergent MHC types (Partidos et al . , 1991; US 5,759,551).
- the Th domain of the subject peptides has from about 10 to about 50 amino acids and preferably from about 10 to about 30 amino acids.
- Th epitopes When multiple Th epitopes are present (i.e., m ⁇ 2), then each Th epitope is independently the same or different. Th segments are contiguous portions of a Th epitope that are sufficient to enhance or stimulate an immune response to the somatostatin peptide (SEQ ID NO:l) and immunological analogs thereof.
- Th epitopes of the present invention include those derived from foreign pathogens including but not limited to, as examples, hepatitis B surface and core antigen helper T cell epitopes (HB S Th and HB C Th) , pertussis toxin helper T cell epitopes (PT Th) , tetanus toxin helper T cell epitopes (TT Th) , measles virus F protein helper T cell epitopes (MV F Th) , Chlamydia trachoma tis major outer membrane protein helper T cell epitopes (CT Th) , diphtheria toxin helper T cell epitopes (DT Th) , Plasmodium falciparum circumsporozoite helper T cell epitopes (PF Th) , Schistosoma mansoni triose phosphate isomerase helper T cell epitopes (SM Th) , and Escherichia coli TraT helper T cell epitopes (Tra
- Th epitopes include idealized artificial Th (e.g., SEQ ID NOS:14) and artificial SSAL Th (e.g., SEQ ID NOS : 7 , 30, 31) .
- Th sites also include functional immunological analogs.
- Functional Th analogs include immune- enhancing analogs, crossreactive analogs and segments of any of these Th epitopes.
- Functional Th analogs further include conservative substitutions, additions, deletions and insertions of from one to about 10 amino acid residues in the Th epitope which do not essentially modify the Th-stimulating function of the Th epitope.
- Crossreactive and functional immunological analogs of the somatostatin peptide may further comprise conservative substitutions, additions, deletions, or insertions of from one to about four amino acid residues provided that the peptide analogs are capable of eliciting immune responses crossreactive with the somatostatin peptides.
- the conservative substitutions, additions, and insertions can be accomplished with natural or non-natural ammo acids as defined herein.
- Preferred peptide immunogens of this invention are the peptides containing the somatostatm peptides or crossreactive and functional immunological analogs thereof; a spacer (e.g., Gly-Gly) ; a Th epitope that s an HB S Th (SEQ ID NO:15), HB c Th (SEQ ID NO:4), MV F Th (SEQ ID NOS:21,29), PT Th (SEQ ID NO:6), TT Th (SEQ ID NO:5); CT Th (SEQ ID NO:27), DT Th (SEQ ID NO:28), an artificial Th (e.g., SEQ ID NOS : 7 , 14 , 30, 31) or an analogue thereof; and, optionally, an Inv domain (SEQ ID NO : 2 ) or analog thereof.
- a spacer e.g., Gly-Gly
- a Th epitope that s an HB S Th (SEQ ID NO:15), HB c Th (
- Peptide compositions which contain cocktails ofthe subject peptide immunogens with two or more ofthe Th epitopes may enhance immunoefficacy in a broader population and thus provide an improved immune response to the somatostatin peptide
- peptide immunogens of this invention can be made by chemical synthesis methods which are well known to the ordinarily skilled artisan. See, for example, Fields et al . , Chapter 3 in Synthetic Peptides : A User' s Guide, ed. Grant, W. H. Freeman & Co., New York, NY, 1992, p. 77. Hence, peptides can be synthesized using tne automated Mer ⁇ field techniques of solid phase synthesis with the ⁇ -NH 2 protected by either t- Boc or F-moc chemistry using side chain protected am o acids on, for example, an Applied Biosystems Peptide Synthesizer Model 430A or 431.
- Preparation of peptide constructs comprising SSALs for Th epitopes can be accomplished by providing a mixture of alternative amino acids for coupling at a given variable position. After complete assembly of the desired peptide immunogen, the resin is treated according to standard procedures to cleave the peptide from the resin and deblock the functional groups on the amino acid side chains. The free peptide is purified by HPLC and characterized biochemically, for example, by amino acid analysis or by sequencing.
- the subject immunogen may also be polymerized. Polymerization can be accomplished for example by reaction between glutaraldehyde and the -NH 2 groups of the lysine residues using routine methodology. By another method, the synthetic
- A-Th-spacer- (somatostatin peptide) " or "(somatostatin peptide) -spacer- (Th) m -A” immunogen can be polymerized or co-polymerized by utilization of an additional cysteine added to the N-terminus of the synthetic "A-Th-spacer- ( somatostatin peptide) or "(somatostatin peptide) -spacer- (Th) m - (A) n " immunogen.
- the subject immunogen may also be prepared as a branched polymer through synthesis of the desired peptide construct directly onto a branched poly-lysyl core resin (Wang, et al . , Science, 1991; 254:285-288) .
- the longer synthetic peptide immunogens can be synthesized by well known recombinant DNA techniques . Any standard manual on DNA technology provides detailed protocols to produce the peptides of the invention.
- a gene encoding a peptide of this invention the amino acid sequence is reverse translated into a nucleic acid sequence, and preferably using optimized codon usage for the organism in which the gene will be expressed.
- a synthetic gene is made, typically by synthesizing overlapping oligonucleotides which encode the peptide and any regulatory elements, if necessary.
- the synthetic gene is inserted in a suitable cloning vector and recombinants are obtained and characterized.
- the peptide is then expressed under suitable conditions appropriate for the selected expression system and host.
- the peptide is purified and characterized by standard methods .
- the efficacy of the peptide composition of the present invention can be established by injecting an animal, for example, rats, with an immunogenic composition comprising peptides of the invention, e.g., SEQ ID NOS: 8-13, 16-20, 22 followed by monitoring the humoral immune response to the somatostatin and crossreactive and functional immunological homologues thereof, as detailed in the Examples.
- Another aspect of this invention provides a peptide composition comprising an immunologically effective amount of one or more of the peptide immunogens of this invention in a pharmaceutically acceptable delivery system.
- the subject peptides can be formulated as a peptide composition using adjuvants, pharmaceutically-acceptable carriers or other ingredients routinely provided in peptide compositions .
- ingredients that can be used in this invention are adjuvants or emulsifiers including alum, incomplete Freund's adjuvant, liposyn, saponin, squalene, L121, emulsigen monophosphyryl lipid A (MPL) , QS21, ISA51, ISA35, ISA206 and ISA 720 as well as the other efficacious adjuvants and emulsifiers.
- the formulations include formulations for immediate release and/or for sustained release, and induction of systemic immunity, which may be accomplished by, for example, immunogen entrapment by or coadministration with microparticles . Such formulations are readily determined by one of ordinary skill in the art.
- the present immunogens can be administered by any convenient route including subcutaneous, oral, intramuscular, or other parenteral or enteral route. Similarly the immunogens can be administered as a single dose or multiple doses. Immunization schedules are readily determined by the ordinarily skilled artisan.
- the peptide composition of the instant invention contain an effective amount of one or more of the peptide immunogens of the present invention and a pharmaceutically acceptable carrier.
- Such a composition in a suitable dosage unit form generally contains about 0.5 ⁇ g to about 1 mg of the immunogen per kg body weight. When delivered in multiple doses, it may be conveniently divided into an appropriate amount per dosage unit form. For example, an initial dose, e.g.
- immunogen represented as a peptide composition of the present invention is to be administered by injection, preferably intramuscularly, followed by repeat (booster) doses. Dosage will depend on the age, weight and general health of the animal as is well known in the vaccine and therapeutic arts.
- the immune response to synthetic somatostatin peptide immunogens can be improved by delivery through entrapment in or on biodegradable microparticles of the type described by O'Hagan et al . ( Vaccine, 1991; 9: 768-771).
- the immunogens can be encapsulated with or without an adjuvant in biodegradable microparticles, to potentiate immune responses, and to provide time-controlled release for sustained or periodic responses, and for oral administration, (O'Hagan et al, 1991; and, Eldridge et al . , 1991; 28: 287-294).
- Peptides listed in Tables 2 and 3 were synthesized individually by the Merrifield solid-phase synthesis technique on Applied Biosystems automated peptide synthesizers (Models 430, 431 and 433A) using Fmoc chemistry.
- Preparation of peptide constructs comprising structured synthetic antigen libraries (SSALs), e.g., artificial Th site termed "1,4,9 PALINDROMIC" (SEQ ID NO:7) can be accomplished by providing a mixture of the desired amino acids for chemical coupling at a given position as specified in the design.
- the resin was treated according to standard procedure using trifluoroacetic acid to cleave the peptide from the resin and deblock the protecting groups on the amino acid side chains.
- the cleaved peptide was dissolved in 15% DMSO in water for 48 hrs to facilitate intradisulfide bond formation between cysteines.
- the cleaved, extracted and washed peptides were purified by HPLC and characterized by mass spectrometry and reverse phase HPLC.
- Peptides marked by "b” in the peptide code column were synthesized as target antigenic peptides in tandem with Th sites as shown.
- Th sites used include, for example, the HBs Th taken from hepatitis B virus (SEQ ID NO:15), and the novel artificial Th site termed "1,4,9 PALINDROMIC" (SEQ ID NO:7).
- Peptides marked by “c” are variants of the "b” constructs synthesized in tandem with the Inv domain immunostimulatory peptide (SEQ ID NO:2).
- Peptides marked by “d” are the reversal of the "b” constructs (e.g., somatostatin-Th) and peptides marked by “e” are the reversal of the "c” constructs (e.g., somatostatin-Th-Inv) .
- the "b”, “c", “d” and “e” constructs were synthesized with gly-gly spacers for separation of the target antigenic site from the Th site, and separation of the Th from the Inv immunostimulatory site.
- Somatostatin Peptide immunogens e.g., SEQ ID NOS: 8-
- Immunogens (1) individual peptide immunogen; or
- Adjuvants (1) Freund's Complete Adjuvant (CFA) / Incomplete Adjuvant (IFA); or
- Alum (Aluminum hydroxide); CFA/IFA groups received CFA week 0, IFA in subsequent weeks. Alum groups received same formulations for all doses Dose Schedule: 0, 2 and 4 weeks; 0, 3, and 6 weeks or otherwise specified.
- Group Size 4 or 5 rats/group Assay: specific ELISAs for each immune serum's anti-peptide activity, solid-phase substrate was the cyclized somatostatin peptide (SEQ ID NO:l) .
- Blood was collected and processed into serum, and stored prior to titering by ELISA with the target antigenic peptides.
- Anti-somatostatin antibody activities were determined by ELISAs (enzyme-linked immunosorbent assays) using 96-well flat bottom microtiter plates which were coated with the cyclized somatostatin peptide (SEQ ID NO:l) as immunosorbent. Aliquots (100 ⁇ L) of the peptide immunogen solution at a concentration of 5 ⁇ g/mL were incubated for 1 hour at 37°C. The plates were blocked by another incubation at 37°C for 1 hour with a 3% gelatin/PBS solution. The blocked plates were then dried and used for the assay.
- ELISAs enzyme-linked immunosorbent assays
- Th peptide-based ELISAs were performed essentially the same as the somatostatin ELISA described herein above except for the antigen coating steps, where microtiter wells were coating for 1 hr at 37° with the designated individual Th peptide derived from its corresponding somatostatin vaccine construct (e.g., peptides with SEQ ID NOS: 14 and 15) at 5 ⁇ g/mL.
- the designated individual Th peptide derived from its corresponding somatostatin vaccine construct e.g., peptides with SEQ ID NOS: 14 and 15
- the somatostatin peptide immunogens shown in Table 2 illustrate variations of the peptides of this invention represented by the formulas:
- A is an amino acid, NH 2 , or Inv (SEQ ID NO:2); when A is an amino acid or Inv it can be linked to either the N-terminal or the C-terminal;
- Th is a helper T cell epitope derived from foreign pathogens, e.g., HBcso-egTh (SEQ ID NO: 4) , TT 6 i5-63iTh (SEQ ID NO:5), PTi49-i76Th (SEQ IP NO: 6), or and artificial Th e.g., 1,4,9 PALIPROMIC Th (SEQ IP NO:7); n is 1, m is 1 and o is 2 These peptides were synthesized among others and immune sera were generated for immunogenicity evaluation.
- Th Most of the peptides shown in Table 2, incorporating various forms and orientations of Th epitopes, elicited high titer somatostatin-specific antibodies in the immunized hosts. In contrast, the somatostatin peptide (pl348a, SEQ IP NO:l) lacking Th was devoid of immunogenicity. However, certain Th are to be preferred over others.
- p2134b (SEQ IP NO:8) having HBc Th (SEQ ID NO:4)
- p2384b (SEQ ID NO:20) having SynTh(l,2,3) (SEQ ID N0:14), an artificial Th site
- p2138b (SEQ ID NO: 10) having PT149-176 Th (SEQ ID NO: 6) are more immunogenic than p2135b (SEQ ID NO: 9) having TT Th (SEQ ID NO:5) and all of these are preferable to p2136b (SEQ ID NO:24) having CTA8 Th (SEQ ID NO:23) which is scarcely immunogenic at all.
- the orientation of the Th site to the somatostatin target site must be specified. Compare the kinetics of the antibody response for p2253b (SEQ ID NO:ll) to p2255d (SEQ ID NO:12). It is preferable to place 1,4,9 PALINDROMIC Th (SEQ ID NO: 7) on the C-terminus of somatostatin. From the comparison of pl344b (SEQ ID NO:16) to pl349b (SEQ ID NO:22), the better placement for MV F2 58- 2 77 (SEQ ID NO: 21) is on the N-terminus of somatostatin. It is clear that the selection and arrangement of each Th site must be specified for the preferred peptides of the invention.
- the antibody titers directed at the immunostimulatory elements e.g., Inv-MVF 2 58-277 Th of pl343c (SEQ ID NO: 17) and KKK-HBS19-32 Th-GG of pl346b (SEQ ID NO: 18) from Table 3, were ⁇ 1 Logio in comparison to those of >3 Logio for somatostatin.
- the immune response generated by the synthetic peptides of the present invention were directed almost exclusively to the somatostatin target site.
- Th is a helper T cell epitope derived from any of the foreign pathogens as shown in Table 4; or, an helper T cell epitope from any of the artificial Th epitopes as shown in Table 5;
- A is an amino acid, ocNH 2 , or an invasin domain (SEQ ID NO: 2) ; when A is an amino acid or Inv it can be linked to either the N-terminus or the C-terminus;
- B is glycine; n is 1, m is 1 and o is 2 are synthesized and immune sera generated.
- Carrier protein-somatostatin conjugates were used as the vaccines for immunization.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10041598A | 1998-06-20 | 1998-06-20 | |
US100415 | 1998-06-20 | ||
PCT/US1999/013923 WO1999066950A1 (en) | 1998-06-20 | 1999-06-21 | Synthetic somatostatin immunogen for growth promotion in farm animals |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1087784A1 true EP1087784A1 (en) | 2001-04-04 |
Family
ID=22279650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99931846A Withdrawn EP1087784A1 (en) | 1998-06-20 | 1999-06-21 | Synthetic somatostatin immunogen for growth promotion in farm animals |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1087784A1 (en) |
JP (1) | JP2002518033A (en) |
CN (1) | CN1311688A (en) |
AU (1) | AU4826799A (en) |
BR (1) | BR9911388A (en) |
CA (1) | CA2329755A1 (en) |
WO (1) | WO1999066950A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229679B (en) * | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
CA2682569A1 (en) * | 2007-03-29 | 2008-10-09 | University Of Southern California | Fusion proteins with cleavable spacers and uses thereof |
NZ590010A (en) * | 2008-06-25 | 2013-01-25 | Braasch Biotech Llc | Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant |
MA40824A (en) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | MODIFIED VIRUS TYPE CMV PARTICLES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812554A (en) * | 1977-11-08 | 1989-03-14 | Genentech, Inc. | Somatostatin peptide conjugate |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
-
1999
- 1999-06-21 CN CN99807401A patent/CN1311688A/en active Pending
- 1999-06-21 WO PCT/US1999/013923 patent/WO1999066950A1/en not_active Application Discontinuation
- 1999-06-21 AU AU48267/99A patent/AU4826799A/en not_active Abandoned
- 1999-06-21 EP EP99931846A patent/EP1087784A1/en not_active Withdrawn
- 1999-06-21 BR BR9911388-0A patent/BR9911388A/en not_active IP Right Cessation
- 1999-06-21 JP JP2000555636A patent/JP2002518033A/en active Pending
- 1999-06-21 CA CA002329755A patent/CA2329755A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9966950A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1311688A (en) | 2001-09-05 |
AU4826799A (en) | 2000-01-10 |
CA2329755A1 (en) | 1999-12-29 |
WO1999066950A1 (en) | 1999-12-29 |
JP2002518033A (en) | 2002-06-25 |
BR9911388A (en) | 2001-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6713301B1 (en) | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens | |
US6025468A (en) | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides | |
EP1089759B1 (en) | Synthetic peptide vaccines for foot-and-mouth disease | |
EP0708656B1 (en) | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines | |
US6780969B2 (en) | Synthetic peptide composition as immunogens for prevention of urinary tract infection | |
WO1999066950A1 (en) | Synthetic somatostatin immunogen for growth promotion in farm animals | |
IE920055A1 (en) | Improvements in and relating to hormones | |
US5864008A (en) | Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides | |
MXPA00011752A (en) | Synthetic somatostatin immunogen for growth promotion in farm animals | |
HU210966B (en) | Method for the preparation of peptides and veterinary compositions containing them | |
KR20220131951A (en) | Peptide immunogen targeting pituitary adenylate cyclase-activating peptide (PACAP) and formulations thereof for the prevention and treatment of migraine | |
AU759183B2 (en) | HIV-specific cytotoxic T-cell responses | |
MXPA00011939A (en) | Artificial t helper cell epitopes as immune stimulators for synthetic peptideimmunogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001218 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040103 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1036750 Country of ref document: HK |